MorphoSys alternatives

Teams often compare MorphoSys with companies offering broad oncology pipelines, established manufacturing and global regulatory expertise such as Roche, AstraZeneca and Bristol Myers Squibb. These players provide comparable or larger late-stage assets and in-house clinical development resources.

MorphoSys historically relied on discovery licensing and co-development deals. Regeneron and Amgen typically combine internal discovery with larger commercial infrastructure and different deal structures, which can affect upfront costs and downstream economics.

Pure-play platform companies such as Adimab or AbCellera focus on discovery services without large therapeutic pipelines, offering an alternative model to MorphoSys integrated approach for groups seeking technology access rather than co-developed assets.

Large pharma like Pfizer, Sanofi and Novartis itself operate extensive biologics manufacturing networks that exceed the historical capacity associated with MorphoSys, making them relevant when commercial supply is a primary concern.

Companies such as Eli Lilly, Merck and AbbVie maintain active oncology and immunology co-development programs and may provide comparable partnership structures for early or mid-stage antibody assets.